Century Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Century Therapeutics has a total shareholder equity of $222.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $416.4M and $194.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$196.40m |
| Equity | US$222.10m |
| Total liabilities | US$194.34m |
| Total assets | US$416.45m |
Recent financial health updates
Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06
We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Recent updates
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
Jun 20Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Feb 01We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
Aug 25Financial Position Analysis
Short Term Liabilities: IPSC's short term assets ($203.5M) exceed its short term liabilities ($19.2M).
Long Term Liabilities: IPSC's short term assets ($203.5M) exceed its long term liabilities ($175.2M).
Debt to Equity History and Analysis
Debt Level: IPSC is debt free.
Reducing Debt: IPSC had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPSC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IPSC has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 19.1% each year.